BioScrip (BIOS) has been under a strong bear grip, hence the stock is down -0.47% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 3.22% in the past 1 week. The stock has risen by 3.77% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.48% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 2.63% and the 50-Day Moving Average is 3.09%.The 200 Day SMA reached 19.86% BioScrip, Inc. is up 11.34% in the last 3-month period. Year-to-Date the stock performance stands at 57.14%.
BioScrip (BIOS) : The highest short term price target forecast on BioScrip (BIOS) is $5 and the lowest target price is $3. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $3.92 with a standard deviation of $1.13.
For the current week, the company shares have a recommendation consensus of Buy. BioScrip (NASDAQ:BIOS): The stock opened at $2.55 and touched an intraday high of $2.78 on Friday. During the day, the stock corrected to an intraday low of $2.55, however, the bulls stepped in and pushed the price higher to close in the green at $2.75 with a gain of 7.42% for the day. The total traded volume for the day was 1,003,174. The stock had closed at $2.75 in the previous trading session.
BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.